LA JOLLA PHARMACEUTICAL COMPANY LJPC Cash Flow

La jolla pharmaceutical company (LJPC)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Operating activities
Net Income (Loss) Attributable to Parent
-8,591	-25,233	-29,174	-30,416	-31,685	-45,418	-50,745	-52,778	-50,528	-38,546	-26,288	-26,729	-23,240	-24,887	-21,251	-15,566	-16,481	-11,833	-10,474	-10,650	-8,955	-6,849	-5,052	-4,284	-5,128	-6,397	-4,174	-3,162	-4,202	-3,105	-2,219	-7,697	5,284	-13,323	3,570	4,714	-6,509
Adjustments to reconcile net loss to net cash used for operating activities:
Share-based compensation expense
2,407	-	-	-	6,782	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share-based compensation expense
-	4,211	6,419	6,392	6,711	6,025	9,880	9,844	9,402	6,619	5,482	4,711	4,983	3,742	3,844	3,337	3,623	2,221	2,826	3,598	2,906	2,397	1,768	2,154	2,673	3,805	2,743	2,295	3,530	-	-	-	-	60	63	63	68
Third party share-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	81	4	82	508	235	282	496	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Third party share-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	25	-	-	-	-	-	-	-	-	-	-	-	-
Gain on adjustment to fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	302	1,227	-4,485	5,954	-	-	-	-
Depreciation and amortization expense
1,060	1,144	1,145	1,133	1,130	1,160	1,157	1,096	992	369	318	300	281	220	200	168	142	138	114	84	11	7	5	3	2	2	2	1	0	-	-	-	-	-	-	-	-
Loss on disposal of equipment
-148	-9	0	0	-15	0	-86	-18	-132	-199	0	0	0	0	0	-54	-21	-16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
1,682	1,804	2,293	2,368	2,310	2,376	2,766	1,655	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash rent expense
345	-	-	-	316	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
592	1,543	-476	-106	618	-156	1,165	372	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory, net
-251	301	-58	-9	-43	919	162	119	820	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash, current portion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-37	0	200	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid clinical expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-98	-991	-79	1,528	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	37	-	-	-	-	-	-	-	-
(Gain) loss on adjustments to fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,029
Prepaid expenses and other current assets
-1,084	-316	-306	-50	28	-736	565	-1,044	3,179	1,375	-3	88	182	4	-42	71	631	-1,171	-138	0	485	-16	5	-8	113	-4	-20	-9	51	-15	-57	47	-10	51	-10	17	-65
Other assets
-	-	-	-	-	-	-	-	-	0	0	-20	-199	0	2	0	147	13	0	0	57	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-2,282	-1,161	430	1,867	-5,531	2,002	501	-1,252	-4,163	5,245	319	1,747	-2,479	4,108	-258	-152	-98	485	724	-616	1,729	47	-234	355	-272	420	254	22	46	3	-22	-31	1	-	-	-	-
Accrued expenses
-2,404	727	-1,306	232	742	-455	1,298	1,031	3,577	32	307	-102	-439	-2,466	1,805	-299	1,187	-467	860	168	-809	26	842	-204	75	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	-1	-12
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	52	-305	226
Accrued payroll and related expenses
-4,683	3,214	1,038	2,044	-5,473	2,587	304	1,574	-1,951	1,767	1,365	953	-1,167	756	526	443	-738	461	219	410	-424	392	-89	12	9	17	15	15	9	-	-	-	-	-76	11	-1	-12
Lease liability
674	-	-	-	618	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	-286	-266	688	688	335	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used for operating activities
-12,249	-17,132	-18,617	-16,515	-32,686	-32,036	-36,911	-37,571	-45,850	-25,355	-18,494	-19,188	-22,044	-18,611	-15,013	-12,082	-13,003	-8,481	-5,460	-5,733	-5,509	-5,404	-2,790	-1,956	-2,729	-2,069	-1,140	-820	-705	-458	-443	-575	-659	-462	-290	-953	-121
Investing activities
Proceeds from the sale of property and equipment
1,143	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
0	19	238	257	184	88	371	887	994	4,906	2,267	1,271	750	799	509	432	478	135	356	934	391	172	30	41	15	3	2	38	0	-	-	-	-	-	-	-	-
Purchase of patent assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	243
Net cash provided by (used for) investing activities
1,143	-19	-238	-257	-184	-88	-371	-887	-994	-4,906	-2,267	-1,271	-750	-799	-509	-432	-478	-135	-356	-934	-391	-172	-30	-41	-15	-3	-2	-38	0	-	-	-	-	-	-	-	-243
Financing activities
Proceeds from the issuance of common stock under ESPP
-	172	177	201	283	391	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of common stock under 2013 Equity Plan
-	31	0	0	0	0	192	1,188	528	334	285	0	2,074	64	0	0	85	28	230	0	57	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from the issuance of common stock
-	-	-	-	-	0	0	0	109,809	0	0	0	117,480	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
505	203	177	201	283	391	192	125,477	110,337	334	285	0	119,554	64	0	0	85	28	104,826	0	57	0	53,063	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and restricted cash
-10,601	-16,948	-18,678	-16,571	-32,587	-31,733	-37,090	87,019	63,493	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	-	-20,476	-20,459	96,760	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of non-cash investing and financing activities:
Conversion of Series F Convertible Preferred Stock into common stock
0	0	0	0	2,737	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Initial recognition of right-of-use lease asset
0	0	0	0	16,798	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciliation of cash and restricted cash to the consolidated balance sheets
Reconciliation of cash and restricted cash to the condensed consolidated balance sheets
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,522	-12,514	-13,396	-8,588	99,010	-6,667	-5,843	-5,576	50,243	-1,997	-2,744	-2,071	8,858	-858	-705	42	-443	-575	-659	-462	-290	-710	-364
Conversion of Series C-1 and D-1 Preferred Stock into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	0	0	5,532
Suspension of preferred stock dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-78